BAAM
NTLA icon

Baker Avenue Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Baker Avenue Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5
Closed -$204 – 1675
2023
Q2 		$204 Buy
+5
New +$203 ﹤0.01% 1575

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Baker Avenue Asset Management's NTLA Position: Q3 2023 in Review

Baker Avenue Asset Management sold out of Intellia Therapeutics (NTLA) in Q3 2023, closing a stake of 5 shares — an estimated $204 sold.

Baker Avenue Asset Management first reported a position in NTLA in Q2 2023 and held it in 1 quarter. The position peaked at $204 in Q2 2023. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2023.

  • Baker Avenue Asset Management reported no remaining Intellia Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 5 Intellia Therapeutics shares in Q3 2023, an estimated $204.
  • Baker Avenue Asset Management first reported a position in Intellia Therapeutics in Q2 2023 and held it in 1 quarter.
  • Baker Avenue Asset Management's Intellia Therapeutics position peaked at $204 in Q2 2023.
  • 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2023.

Based on Baker Avenue Asset Management's 13F filing for Q3 2023, filed 15 Nov 2023.